Literature DB >> 11313935

BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.

F Lin1, G Monaco, T Sun, J Liu, H Lin, C Stephens, J Belmont, R B Arlinghaus.   

Abstract

It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML). We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl. To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity. Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001. Of interest, mice that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50. We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313935     DOI: 10.1038/sj.onc.1204409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

2.  Bcr is a negative regulator of the Wnt signalling pathway.

Authors:  Angelika Ress; Karin Moelling
Journal:  EMBO Rep       Date:  2005-10-07       Impact factor: 8.807

3.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

4.  Lipocalin 2 is required for BCR-ABL-induced tumorigenesis.

Authors:  X Leng; H Lin; T Ding; Y Wang; Y Wu; S Klumpp; T Sun; Y Zhou; P Monaco; J Belmont; A Aderem; S Akira; R Strong; R Arlinghaus
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

5.  Requirement of lipocalin 2 for hematopoietic and solid tumor malignancies.

Authors:  Xiaohong Leng; Tian Ding; Ralph Arlinghaus
Journal:  Adv Enzyme Regul       Date:  2009-01-20

6.  Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.

Authors:  B Perazzona; H Lin; T Sun; Y Wang; R Arlinghaus
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

Review 7.  Signaling Pathways That Regulate Normal and Aberrant Red Blood Cell Development.

Authors:  Mark C Wilkes; Aya Shibuya; Kathleen M Sakamoto
Journal:  Genes (Basel)       Date:  2021-10-19       Impact factor: 4.141

8.  The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Anahita Rafiei; Afsar Ali Mian; Claudia Döring; Anna Metodieva; Claudia Oancea; Frederic B Thalheimer; Martin Leo Hansmann; Oliver Gerhard Ottmann; Martin Ruthardt
Journal:  PLoS Genet       Date:  2015-04-28       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.